| Claire L Rosen, MS OTR/L | |
|
514 Riverview Ave, Waukesha, WI 53188-3631 | |
| (262) 424-0346 | |
| Not Available |
| Full Name | Claire L Rosen |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 514 Riverview Ave, Waukesha, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194041384 | NPI | - | NPPES |
| 41205000 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 487526 (Wisconsin) | Primary |
| Provider Name | Integrative Psyche, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1255704565 PECOS PAC ID: 6608176342 Enrollment ID: O20151201002896 |
News Archive
For most adolescents, playing video games is an enjoyable and often social form of entertainment. While playing video games is a fun pastime, there is a growing concern that spending too much time playing video games is related to negative developmental outcomes and can become an addiction.
An international team of researchers has found that adding a humanized monoclonal antibody called daclizumab to standard treatment reduces the number of new or enlarged brain lesions in patients with relapsing multiple sclerosis. This new study was published online Feb. 16, 2010, and in the March edition of the Lancet Neurology.
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
The TACKLE CANCER FOUNDATION wants to call attention to important news for patients with the blood cancer multiple myeloma. A new study shows patients benefit from daily medical treatments to keep their cancer in check after they have had a stem cell (bone marrow) transplant. The current standard of care is to give patients the transplant and then hold off on additional treatment until they relapse. The new study shows continuous treatment with the oral drug REVLIMID following the transplant significantly prolongs remission, increasing time to disease progression.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Claire L Rosen, MS OTR/L 647 W Virginia St, Milwaukee, WI 53204-1535 Ph: (414) 325-3082 | Claire L Rosen, MS OTR/L 514 Riverview Ave, Waukesha, WI 53188-3631 Ph: (262) 424-0346 |
News Archive
For most adolescents, playing video games is an enjoyable and often social form of entertainment. While playing video games is a fun pastime, there is a growing concern that spending too much time playing video games is related to negative developmental outcomes and can become an addiction.
An international team of researchers has found that adding a humanized monoclonal antibody called daclizumab to standard treatment reduces the number of new or enlarged brain lesions in patients with relapsing multiple sclerosis. This new study was published online Feb. 16, 2010, and in the March edition of the Lancet Neurology.
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
The TACKLE CANCER FOUNDATION wants to call attention to important news for patients with the blood cancer multiple myeloma. A new study shows patients benefit from daily medical treatments to keep their cancer in check after they have had a stem cell (bone marrow) transplant. The current standard of care is to give patients the transplant and then hold off on additional treatment until they relapse. The new study shows continuous treatment with the oral drug REVLIMID following the transplant significantly prolongs remission, increasing time to disease progression.
› Verified 7 days ago
Jo Meek, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1451 Cleveland Ave, Waukesha, WI 53186 Phone: 262-547-2123 | |
Mrs. Linda Marie Wetzel, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 500 Riverview Ave, Waukesha, WI 53188 Phone: 262-424-0094 Fax: 262-896-6879 | |
Mrs. Lynn Marie Knull, OTR Occupational Therapist Medicare: Medicare Enrolled Practice Location: 1451 Cleveland Ave, Waukesha, WI 53186 Phone: 262-547-2123 | |
Mrs. Susan Vaughan Kratz, OTR, CST Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: W238n1690 Rockwood Dr, Suite 500, Waukesha, WI 53188 Phone: 262-347-2222 Fax: 262-347-2251 | |
Kristen N Kemos, MOT Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 1111 Delafield St, Ste 120, Waukesha, WI 53188 Phone: 262-521-9762 Fax: 262-521-1091 | |
Rachel Urban, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: S52w23111 Hunters Holw, Waukesha, WI 53189 Phone: 262-825-8731 | |
Amanda Ann Ortiz, MS, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 514 Riverview Ave, Waukesha, WI 53188 Phone: 262-896-6829 Fax: 262-896-6879 |